Skip to main content
SpringerLink
Log in

Anemia in Dialysis Patients

  • Chapter
  • First Online:
Complications in Dialysis

  • 195 Accesses

Abstract

Anemia is a common complication of chronic kidney disease (CKD), and it is associated with high morbidity and mortality. The perspective of anemia treatment was altered after 1989 when the FDA approved the use of erythropoiesis-stimulating agents (ESAs). Ever since, several studies tried to establish how to best target hemoglobin levels aiming to reduce complications associated with low and high hemoglobin. Most CKD guidelines recommend similar parameters for initiating and discontinuing ESA and IV iron replacement therapy. The association of CKD with other comorbidities is an additional challenge in the management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13(7):1928–36.

    Article  PubMed  Google Scholar 

  2. Minutolo R, Provenzano M, Chiodini P, Borrelli S, Garofalo C, Andreucci M, Liberti ME, Bellizzi V, Conte G, De Nicola L, Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology. New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study. Clin Kidney J. 2022;15(6):1120–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Palaka E, Grandy S, van Haalen H, et al. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes: a systematic literature review. Int J Nephrol. 2020;2020:7692376.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–22.

    Article  CAS  PubMed  Google Scholar 

  5. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37(2):395–402.

    Article  PubMed  Google Scholar 

  7. Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(2):153–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Anonymous. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5–37.

    Google Scholar 

  9. Bruce G, Schulga P, Reynolds BC. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review. Clin Kidney J. 2022;15(8):1483–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zadrazil J, Horak P. Pathophysiology of anemia in chronic kidney diseases: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):197–202.

    Article  PubMed  Google Scholar 

  11. Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011;80(3):240–4.

    Article  CAS  PubMed  Google Scholar 

  12. Panwar B, Gutiérrez OM. Disorders of iron metabolism and anemia in chronic kidney disease. Semin Nephrol. 2016;36(4):252–61.

    Article  CAS  PubMed  Google Scholar 

  13. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis. 2009;16(2):94–100.

    Article  PubMed  Google Scholar 

  14. Nangaku M, Mimura I, Yamaguchi J, Higashijima Y, Wada T, Tanaka T. Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients. J Ren Nutr. 2015;25(2):160–3.

    Article  CAS  PubMed  Google Scholar 

  15. KDIGO Anemia Work Group. KDIGO clinical practice Guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.

    Google Scholar 

  16. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant. 2004;19:121–32.

    Article  PubMed  Google Scholar 

  17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):53–61. https://doi.org/10.1016/s0272-6386(96)90130-4.

    Article  CAS  PubMed  Google Scholar 

  18. Pecorelli S. Suboptimal hemoglobin levels: do they impact patients and their therapy? Semin Oncol. 2000;27(suppl 4):1–3.

    CAS  PubMed  Google Scholar 

  19. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol. 2002;13(6):965–73.

    Article  CAS  PubMed  Google Scholar 

  20. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000.

    Article  CAS  PubMed  Google Scholar 

  21. Procrit [package insert]. Thousand Oaks: Amgen Inc.; 1993.

    Google Scholar 

  22. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77(2):176–85.

    Article  CAS  PubMed  Google Scholar 

  23. Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol. 1989;64(3):222–4.

    Article  CAS  PubMed  Google Scholar 

  24. National Kidney Foundation Anemia Working Group. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-dialysis outcomes quality initiative. Am J Kidney Dis. 1997;30(4 Suppl 3):S192–240.

    Google Scholar 

  25. Auer J, Simon G, Stevens J, Griffiths P, Howarth D, Anastassiades E, et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int. 1992;12(1):40–2.

    Article  CAS  PubMed  Google Scholar 

  26. Paganini EP. In search of an optimal hematocrit level in dialysis patients: rehabilitation and quality-of-life implications. Am J Kidney Dis. 1994;24(1 Suppl 1):S10–6.

    CAS  PubMed  Google Scholar 

  27. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25(4):548–54.

    Article  CAS  PubMed  Google Scholar 

  28. Ritz E, Zeier M, Schneider P, Jones E. Cardiovascular mortality of patients with polycystic kidney disease on dialysis: is there a lesson to learn? Nephron. 1994;66(2):125–8.

    Article  CAS  PubMed  Google Scholar 

  29. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol. 1990;6(1):1–4.

    CAS  PubMed  Google Scholar 

  30. Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol. 2008;3(6):1669–75.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Junor BJ. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful. Perit Dial Int. 1993;13(Suppl 2):S535–7.

    Article  PubMed  Google Scholar 

  32. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.

    Article  CAS  PubMed  Google Scholar 

  33. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.

    Article  CAS  PubMed  Google Scholar 

  34. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal hematocrit trial. Kidney Int. 2012;82(2):235–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381–8.

    Article  CAS  PubMed  Google Scholar 

  36. Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–59.

    Article  CAS  PubMed  Google Scholar 

  37. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI US commentary on the 2012 KDIGO clinical practice Guideline for anemia in CKD. Am J Kidney Dis. 2013;62(5):849–59.

    Article  PubMed  Google Scholar 

  38. Padhi S, Glen J, Pordes BA, Thomas ME, Guideline Development Group. Management of anaemia in chronic kidney disease: summary of updated NICE guidance. BMJ. 2015;350:h2258.

    Article  PubMed  Google Scholar 

  39. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rosenblatt SG, Drake S, Fadem S, Welch R, Lifschitz MD. Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis. 1982;1(4):232–6.

    Article  CAS  PubMed  Google Scholar 

  41. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004;22(1):112–23.

    Article  CAS  PubMed  Google Scholar 

  42. Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677–90.

    Article  CAS  PubMed  Google Scholar 

  43. Li X, Cole SR, Kshirsagar AV, Fine JP, Sturmer T, Brookhart MA. Safety of dynamic intravenous iron administration strategies in hemodialysis patients. Clin J Am Soc Nephrol. 2019;14(5):728–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. Am J Nephrol. 2018;48(4):260–8.

    Article  CAS  PubMed  Google Scholar 

  45. Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012;122(10):3529–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, et al. Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol. 2018;47(2):72–83.

    Article  CAS  PubMed  Google Scholar 

  47. Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, van der Kallen CJ, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care. 2013;36(2):309–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bazeley J, Wish JB. The evolution of target hemoglobin levels in anemia of chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(4):229–36.

    Article  PubMed  Google Scholar 

  49. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESAs). Clin J Am Soc Nephrol. 2009;4(2):470–80.

    Article  CAS  PubMed  Google Scholar 

  50. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:Cd003407.

    PubMed  Google Scholar 

  51. Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017;92(2):306–12.

    Article  CAS  PubMed  Google Scholar 

  52. Brenner N, Kommalapati A, Ahsan M, Ganguli A. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. J Nephrol. 2020;33(2):267–75.

    Article  PubMed  Google Scholar 

  53. Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end-stage renal disease. Semin Dial. 2012;25(5):539–44.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Alam A, Lin Y, Lima A, Hansen M, Callum JL. The prevention of transfusion-associated circulatory overload. Transfus Med Rev. 2013;27(2):105–12.

    Article  PubMed  Google Scholar 

  55. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–35.

    Article  PubMed  Google Scholar 

  56. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774–89.

    Article  PubMed  Google Scholar 

  57. Oakley FD, Woods M, Arnold S, Young PP. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion. 2015;55(3):563–70.

    Article  PubMed  Google Scholar 

  58. Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007;47(6):1089–96.

    Article  PubMed  Google Scholar 

  59. Obrador GT, Macdougall IC. Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol. 2013;8(5):852–60.

    Article  PubMed  Google Scholar 

  60. Dhillon S. Roxadustat: first global approval. Drugs. 2019;79(5):563–72.

    Article  CAS  PubMed  Google Scholar 

  61. Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187–99.

    Article  CAS  PubMed  Google Scholar 

  62. Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27(4):1225–33.

    Article  CAS  PubMed  Google Scholar 

  63. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral Roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–22.

    Article  CAS  PubMed  Google Scholar 

  66. Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Ther Apher Dial. 2020;24(2):115–25.

    Article  CAS  PubMed  Google Scholar 

  67. Mokas S, Lariviere R, Lamalice L, Gobeil S, Cornfield DN, Agharazii M, et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. Kidney Int. 2016;90(3):598–609.

    Article  CAS  PubMed  Google Scholar 

  68. Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26(4):253–66.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014;9(11):e111838.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234–44.

    Article  CAS  PubMed  Google Scholar 

  72. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40(5):302–9. https://doi.org/10.1159/000356193.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs. 2013;73:117–30.

    Article  PubMed  Google Scholar 

  74. Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Jelkmann W. Activin receptor ligand traps in chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(5):351–7.

    Article  CAS  PubMed  Google Scholar 

  76. Locatelli F, Del Vecchio L, Luise MC. Current and future chemical therapies for treating anaemia in chronic kidney disease. Expert Opin Pharmacother. 2017;18(8):781–8.

    Article  CAS  PubMed  Google Scholar 

  77. López-Gómez JM, Abad S, Vega A. New expectations in the treatment of anemia in chronic kidney disease. Nefrología (English Edition). 2016;36(3):232–6.

    Article  Google Scholar 

  78. Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs. 2016;25(8):901–16.

    Article  CAS  PubMed  Google Scholar 

  79. Nasr R, Chilimuri S. Preoperative evaluation in patients with end-stage renal disease and chronic kidney disease. Health Serv Insights. 2017;10:117863291771302.

    Article  Google Scholar 

  80. Trainor D, Borthwick E, Ferguson A. Perioperative management of the hemodialysis patient. Semin Dial. 2011;24(3):314–26.

    Article  PubMed  Google Scholar 

  81. Han J, Zhou J, Kondragunta V, Zhang X, Molokie RE, Gowhari M, et al. Erythropoiesis-stimulating agents in sickle cell anaemia. Br J Haematol. 2017;182(4):602–5. https://doi.org/10.1111/bjh.14846.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Boyle SM, Jacobs B, Sayani FA, Hoffman B. Management of the dialysis patient with sickle cell disease. Semin Dial. 2015;29(1):62–70.

    Article  PubMed  Google Scholar 

  83. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  84. Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902–10.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist. 2011;16(S3):35–42.

    Article  PubMed  Google Scholar 

  86. Ayari H, Pasquier F, Karoui KE, Sallée M, Faguer S, Krummel T, et al. Myelodysplastic syndrome in hemodialysis patients. Kidney Int Rep. 2019;4(8):1175–8.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Chang M-Y, Lin S-F, Wu S-C, Yang W-C. Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis. Sci Rep. 2020;10(1):15557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Hara R, Goto N, Furuya D, Kitahara T, Numata H, Watanabe S, et al. The effect of roxadustat on transfusion-dependent myelodysplastic syndrome complicated by chronic kidney disease. Case Rep Oncol. 2021;14(3):1574–9.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Tomlinson D, Robinson PD, Oberoi S, Cataudella D, Culos-Reed N, Davis H, et al. Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. Curr Oncol. 2018;25(2):152–67.

    Article  Google Scholar 

  90. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.

    Article  PubMed  Google Scholar 

  91. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996–5010.

    Article  PubMed  Google Scholar 

  92. Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, et al. Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008;26(14):2342–9.

    Article  CAS  PubMed  Google Scholar 

  93. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Cancer-and Chemotherapy-Induced Anemia. NCCN.org. https://oncolife.com.ua/doc/nccn/Cancer-and_Chemotherapy-Induced_Anemia.pdf. Accessed 22 Nov 2019.

  94. Saha M, Allon M. Diagnosis, treatment, and prevention of hemodialysis emergencies. Clin J Am Soc Nephrol. 2017;12(2):357–69.

    Article  CAS  PubMed  Google Scholar 

  95. Greenberg KI, Choi MJ. Hemodialysis emergencies: core curriculum 2021. Am J Kidney Dis. 2021;77(5):796–809.

    Article  PubMed  Google Scholar 

  96. Yoon J, Thapa S, Chow RD, Jaar BG. Hemolysis as a rare but potentially life-threatening complication of hemodialysis: a case report. BMC Res Notes. 2014;28(7):475.

    Article  Google Scholar 

  97. Tharmaraj D, Kerr PG. Haemolysis in haemodialysis. Nephrology (Carlton). 2017;22(11):838–47.

    Article  PubMed  Google Scholar 

  98. Fluck S, McKane W, Cairns T, Fairchild V, Lawrence A, Lee J, Murray D, Polpitiye M, Palmer A, Taube D. Chloramine-induced haemolysis presenting as erythropoietin resistance. Nephrol Dial Transplant. 1999;14(7):1687–91.

    Article  CAS  PubMed  Google Scholar 

  99. Orringer EP, Mattern WD. Formaldehyde-induced hemolysis during chronic hemodialysis. N Engl J Med. 1976;294(26):1416–20. https://doi.org/10.1056/NEJM197606242942602.

    Article  CAS  PubMed  Google Scholar 

  100. Duffy R, Tomashek K, Spangenberg M, Spry L, Dwyer D, Safranek TJ, Ying C, Portesi D, Divan H, Kobrenski J, Arduino M, Tokars J, Jarvis W. Multistate outbreak of hemolysis in hemodialysis patients traced to faulty blood tubing sets. Kidney Int. 2000;57(4):1668–74.

    Article  CAS  PubMed  Google Scholar 

  101. Malinauskas RA. Decreased hemodialysis circuit pressures indicating postpump tubing kinks: a retrospective investigation of hemolysis in five patients. Hemodial Int. 2008;12(3):383–93.

    Article  PubMed  Google Scholar 

  102. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil

    Ana Flávia Moura & José A. Moura-Neto

  2. Clinical and Academic Unit of Nephrology, Hospital Universitário Pedro Ernesto, Faculty of Medical Sciences, Rio de Janeiro State University, Rio de Janeiro, Brazil

    Joan Araujo Oliveira Moitinho & José H. R. Suassuna

  3. Moinhos de Vento Hospital, Porto Alegre, Rio Grande do Sul, Brazil

    Lucas G. da Luz

Authors
  1. Ana Flávia Moura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Araujo Oliveira Moitinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucas G. da Luz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José H. R. Suassuna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José A. Moura-Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José A. Moura-Neto .

Editor information

Editors and Affiliations

  1. Section of Nephrology, Baylor College of Medicine, Houston, TX, USA

    Stephen Z. Fadem

  2. Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil

    José A. Moura-Neto

  3. Salisbury, VT, USA

    Thomas A. Golper

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Moura, A.F., Moitinho, J.A.O., da Luz, L.G., Suassuna, J.H.R., Moura-Neto, J.A. (2023). Anemia in Dialysis Patients. In: Fadem, S.Z., Moura-Neto, J.A., Golper, T.A. (eds) Complications in Dialysis. Springer, Cham. https://doi.org/10.1007/978-3-031-44557-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-44557-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-44556-9

  • Online ISBN: 978-3-031-44557-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation